Adenosine SPECT Thallium Imaging

Article Author:
Talal Alzahrani
Article Editor:
Roman Zeltser
Updated:
2/16/2019 12:53:57 PM
PubMed Link:
Adenosine SPECT Thallium Imaging

Introduction

Adenosine single-photon emission computed tomography (SPECT) thallium (Tl-201) imaging is a non-invasive myocardial perfusion imaging (MPI) test.[1] Currently, SPECT Tl-201 is used mainly for myocardial viability assessment when positron emission tomography (PET) or magnetic resonance imaging viability assessment is not feasible. American Society of Nuclear Cardiology (ASNC) recommend against using adenosine SPECT Tl-201/technetium 99m, dual-isotope (rest-stress), imaging for detecting myocardial ischemia because this protocol has high radiation exposure (up to 23 mSv) compared to other isotopes.[2] Tl-201 is a potassium analog, a radioactive isotope of thallium with a half-life of 73 hours, which is up-taken by myocardial cells and detects an area with hypo-perfusion and myocardial infarction as a cold spot. It has many other medical applications such as renal medullary imaging and tumor detection.[3] In clinical practice, technetium 99m agents (Tc-99m sestamibi and Tc-99m tetrofosmin) are more commonly used with SPECT imaging to detect myocardial ischemia because of low radiation exposure (4.2–6.3 mSv) compared to Tl-201.[2]

Adenosine is a nucleoside that is composed of adenine and d-ribose, a potent coronary vasodilator through activation of A2A receptors in smooth muscles and endothelium.[4] It is used as a continuous infusion in pharmacological SPECT stress test for patients who can not exercise to increase coronary blood flow and radioisotopes uptake by myocardial cells with normal coronary perfusion. Adenosine has several side effects that correlate with the activation of other receptors such as A1AR, A2B, and A3AR. These sides effects are hypotension, tachycardia, atrioventricular block, bronchospasm, peripheral vasodilatation, and gastrointestinal symptoms.[5] Other vasodilator agents that are also usable for pharmacological SPECT stress test are dipyridamole and regadenoson. Regadenoson is an adenosine derivative and selective A2A receptor agonist. Compared to adenosine, regadenoson dosing is as one injection because of long half-life, and it has a more favorable side effect profile because of its selectivity to the A2A receptor.[6] Therefore, regadenoson is the most common pharmacologic vasodilator that is currently used in pharmacological SPECT stress test (83%).[7]

Indications

  1. Indications for pharmacological SPECT stress test include patients who are unable to exercise or have disabling comorbidity for the following purposes[8]:
    1. To diagnose obstructive coronary artery disease (CAD) in patients with intermediate to high pretest probability of ischemic heart disease (IHD) (Class I)
    2. For risk assessment in patients who are known to have stable IHD, especially with LBBB (Class I)
    3. To evaluate coronary stenosis with uncertain physiological significance before revascularization (Class I)
    4. To evaluate new or worsening symptoms not consistent with an acute coronary syndrome (ACS) in patients who have stable IHD (Class I)
    5. For follow-up assessment at 2-year or longer intervals in patients who have stable IHD with previous evidence of silent ischemia or with elevated risk for a recurrent cardiac event, who have a history of incomplete coronary revascularization with an uninterpretable EKG (Class IIa)
  2. Pharmacological SPECT stress test is appropriate for patients who are unable to exercise or have disabling comorbidity for the following purposes[9]:
    1. For new-onset or newly diagnosed heart failure with LV systolic dysfunction
    2. For ventricular tachycardia regardless the risk for CAD
    3. For syncope in patients with intermediate or high risk for CAD
    4. For elevated troponin in patients without additional evidence of ACS
    5. For patients with possible ACS with no evidence of ischemia in EKG and negative or minimally elevated troponin
    6. For patients with intermediate or high-risk Duke treadmill score
    7. For follow-up assessment at five years after CABG
    8. For asymptomatic patients with high IHD risk (ATP III risk criteria)
    9. If prior noninvasive evaluation equivocal, borderline, or discordant stress testing
    10. For coronary calcium Agatston score greater than 400 or greater than 100 with high risk for IHD
    11. Pre-operative risk assessment in intermediate-risk surgery or vascular surgery for patients with one or greater clinical risk factor and poor functional capacity (< 4 METs)
    12. Viability test for patients with severe LV systolic dysfunction before revascularization
    13. To evaluate for inducible ischemia within three months of an acute coronary syndrome in patients who are hemodynamically stable without recurrent symptoms or signs of heart failure

Contraindications

Absolute Contraindications:

The pharmacological vasodilators are contraindicated in the following cases[2]:

  1. Obstructive lung disease with ongoing wheezing or a history of reactive airway disease
  2. Second- or third-degree AV block without a pacemaker
  3. Sinus node disease without a pacemaker
  4. Systolic BP < 90 mmHg, especially in the following scenarios:
    1. Autonomic dysfunction
    2. Hypovolemia
    3. Left main coronary artery stenosis
    4. Stenotic valvular heart disease
    5. Pericarditis or pericardial effusions
    6. Stenotic carotid artery disease with cerebrovascular insufficiency
  5. Uncontrolled hypertension (systolic BP greater than 200 mmHg or diastolic BP greater than 110 mmHg)
  6. Recent (less than48 hours) use of dipyridamole or acetylsalicylic acid/dipyridamole
  7. Known hypersensitivity to pharmacological vasodilators
  8. Acute coronary syndromes
  9. Recent (2 to 4 days) after acute myocardial infarction

Relative Contraindications:

  1. Sinus bradycardia with heart rates less than 40 beats per minute
  2. Mobitz Type 1 second-degree AV block
  3. Ingestion of caffeinated foods/beverages within the last 12 hours
  4. Severe aortic stenosis
  5. Seizure disorder

Personnel

The study should take place under the supervision of a board-certified nuclear cardiologist or nuclear radiologist. 

Preparation

Patients should avoid oral intake for three hours prior to the test except for medications with sips of water. Patients should avoid any medications that contain methylxanthines or caffeine and, food/beverages with caffeine for 12 hours because these products interfere with the action of pharmacological vasodilators and lead to poor image quality.[10] Dipyridamole should also be avoided for 48 hours prior to the test because it can lead to severe hypotension. Patients should avoid wearing any metals or other potential attenuators (e.g., bras with under-wire) because these objects may lead to attenuation artifacts and poor image quality.

Technique

There are many protocols for pharmacological SPECT study. The following protocols are the two most common protocols that are used in the clinical practice[2]:

1- Tl-201 stress/redistribution rest:

This test is a perfusion test and a viability test. The following are the steps of this protocol:

  1. A patient is injected with pharmacological vasodilator (adenosine (140 mcg/kg/min continuous infusion for six minutes) or regadenoson (one dose of 0.4 mg injection)) and a Tl-201 radio-tracer
  2. Stress cardiac images are then taken after 15 minutes with gamma cameras
  3. Rest cardiac images are then taken after 2.5 to 4 hours with gamma cameras. (This step is optional based on the stress cardiac images)
  4. Redistribution cardiac images are then taken after 24 hours from the initial injection with gamma cameras. (This step is optional based on the stress and rest cardiac images)

2- Tl-201 rest/redistribution:

This protocol used for a viability test only. The following are the steps of this protocol:

  1. A patient is injected with a Tl-201 radio-tracer at rest
  2. Rest cardiac images are then taken after 15 minutes with gamma cameras
  3. Redistribution cardiac images are then taken after 3 to 4 hours or 24 hours from the initial injection with gamma cameras. (This step is optional based on the stress and rest cardiac images)

Complications

Most of the side effects of this test are related to pharmacological vasodilators and are usually self-limited. However, these drugs have correlations with a severe side effect such as myocardial infarction.[11][12] The common side effects of these drugs are flushing, headache, chest discomfort, dyspnea, gastrointestinal discomfort, lightheadedness/dizziness, AV block, paresthesia, hypotension, nervousness, and arrhythmias. Aminophylline (50 to 250 mg) or caffeine should be used to reverse the effects of pharmacological vasodilator if a patient develops severe side effects such as hypotension with SBP less than 80 mmHg, 2nd or 3rd degree AV block, arrhythmia, wheezing, severe chest pain with ST-segment depression, or signs of poor perfusion.[2]

Clinical Significance

SPECT stress test has been shown to have excellent diagnostic and prognostic values for IHD. The sensitivity, specificity, and accuracy of SPECT stress test for the diagnosis of coronary artery disease are 82%, 76%, and 83%, respectively.[13] The risk of cardiac events (cardiac death or myocardial infarction) in patients with normal SPECT scan is less than 1% per year. The rate of cardiac events increases significantly with worsening in cardiac images scan findings.[14][15]

Enhancing Healthcare Team Outcomes

Healthcare workers including nurse practitioners should be familiar with the SPECT thallium imaging study. It is a tool to assess for myocardial viability when other tests are not available. A nuclear-cardiologist usually performs the test. The SPECT stress test has been shown to have excellent diagnostic and prognostic values for IHD. The sensitivity, specificity, and accuracy of SPECT stress test for the diagnosis of coronary artery disease are 82%, 76%, and 83%, respectively.[13]